medigraphic.com
ISSN 0326-3428 (Impreso)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2024, Número 2

<< Anterior Siguiente >>

Rev Nefrol Dial Traspl 2024; 44 (2)


Observando la brecha en la atención renal: Traduciendo lo que conocemos a lo que hacemos

Luyckx VA, TuttleKR, Abdellatif D, Correa-Rotter R, Fung WWS; Haris A, Hsiao Li-Li, Khalife M, Kumaraswami LA, Loud F, Raghavan V, Roumeliotis S, Sierra M, Ulasi I, WangB, Lui Siu-Fai, Liakopoulos VBA

Idioma: Ingles.
Referencias bibliográficas: 67
Paginas: 52-70
Archivo PDF: 840.04 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. K.J. Jager, C. Kovesdy, R. Langham et al. A singlenumber for advocacy and communication-worldwidemore than 850 million individuals have kidneydiseases. Kidney Int 96 (2019) 1048–1050.

  2. Institute for Health Metrics and Evaluation (IHME).GBD compare data visualization. Accessed November18, 2023. http://vizhub.healthdata.org/gbd-compare.

  3. V.A. Luyckx, M. Tonelli, J.W. Stanifer, The globalburden of kidney disease and the sustainabledevelopment goals. Bull World Health Organ 96(2018) 414–422D.

  4. International Society of Nephrology. ISN GlobalKidney Health Atlas, 3rd ed. Accessed November18, 2023. https://www.theisn.org/initiatives/globalkidney-health-atlas/.

  5. GBD Chronic Kidney Disease Collaboration. Global,regional, and national burden of chronic kidneydisease, 1990-2017: a systematic analysis for the GlobalBurden of Disease Study 2017. Lancet 395 (2020)709–733.

  6. R. Vanholder, L. Annemans, E. Brown et al. Reducingthe costs of chronic kidney disease while deliveringquality health care: a call to action. Nat. Rev. Nephrol.13 (2017) 393–409.

  7. H.Y. Nguyen-Thi, T.N. Le-Phuoc, N. Tri Phat et al.The economic burden of chronic kidney disease inVietnam. Health Serv Insights 14, 2021.

  8. US Renal Data System. Healthcare expendituresfor persons with CKD. https://usrds-adr.niddk.nih.gov/2023/chronic-kidney-disease/6-healthcareexpenditures-for-persons-with-ckd.

  9. Kidney Health Australia. Transforming Australia’skidney health: a call to action for early detection andtreatment of chronic kidney disease. Accessed January16, 2024. https://kidney.org.au/uploads/resources/Changing-the-CKD-landscape-Economic-benefits-ofearly-detection-and-treatment.pdf.

  10. C. Ke, J. Liang, M. Liu et al. Burden of chronickidney disease and its risk-attributable burden in 137low-and middle-income countries, 1990-2019: resultsfrom the global burden of disease study 2019. BMCNephrol 23 (2022) 17.

  11. E.W. Gregg, J. Buckley, M.K. Ali et al. Improvinghealth outcomes of people with diabetes: target settingfor the WHO Global Diabetes Compact. Lancet 401(2023) 1302–1312.

  12. P. Geldsetzer, J. Manne-Goehler, M.E. Marcus et al.The state of hypertension care in 44 low-income andmiddle-income countries: a cross-sectional study ofnationally representative individual-level data from 1.1million adults. Lancet 394 (2019) 652–662.

  13. L. Chu, S.K. Bhogal, P. Lin et al. AWAREness ofDiagnosis and Treatment of Chronic Kidney Diseasein Adults With Type 2 Diabetes (AWARE-CKD inT2D). Can J Diabetes 46 (2022) 464–472.

  14. A. Levin, M. Tonelli, J. Bonventre et al. Globalkidney health 2017 and beyond: a roadmap for closinggaps in care, research, and policy. Lancet 390 (2017)1888–1917.

  15. B. Stengel, D. Muenz, C. Tu et al. Adherence to theKidney Disease: Improving Global Outcomes CKDguideline in nephrology practice across countries.Kidney Int Rep 6 (2021) 437–448.

  16. C.D. Chu, M.H. Chen, C.E. McCulloch et al.Patient awareness of CKD: a systematic review andmeta-analysis of patient-oriented questions and studysetting. Kidney Med 3 (2021) 576–585.e1.

  17. B. Ene-Iordache, N. Perico, B. Bikbov et al. Chronickidney disease and cardiovascular risk in six regionsof the world (ISN-KDDC): a cross-sectional study.Lancet Global Health 4 (2016) e307–e319.

  18. B. Gummidi, O. John, A. Ghosh et al. A systematicstudy of the prevalence and risk factors of CKD inUddanam, India. Kidney Int Rep 5 (2020) 2246–2255.

  19. Kidney Disease: Improving Global Outcomes(KDIGO) Diabetes Work Group. KDIGO 2022Clinical Practice Guideline for Diabetes Managementin Chronic Kidney Disease. Kidney Int 102 (5S)(2022) S1–S127.

  20. S.B. Nicholas, K.B. Daratha, R.Z. Alicic et al.Prescription of guideline-directed medical therapies inpatients with diabetes and chronic kidney disease fromthe CURE-CKD Registry, 2019-2020. Diabetes ObesMetab 25 (2023) 2970–2979.

  21. M.E. Grams, W. Yang, C.M. Rebholz et al. Risks ofadverse events in advanced CKD: the Chronic RenalInsufficiency Cohort (CRIC) study. Am J Kidney Dis70 (2017) 337–346.

  22. Kidney Disease: Improving Global Outcomes(KDIGO) CKD Work Group. KDIGO 2024 ClinicalPractice Guideline for the Evaluation and Managementof Chronic Kidney Disease. Kidney Int. https://doi.org/10.1016/j.kint.2023.10.018

  23. Kidney Disease: Improving Global Outcomes(KDIGO) Blood Pressure Work Group. KDIGO2021 clinical practice guideline for the management ofblood pressure in chronic kidney disease. Kidney Int99 (3S) (2021) S1–S87.

  24. K.R. Tuttle, R.Z. Alicic, O.K. Duru et al. Clinicalcharacteristics of and risk factors for chronic kidneydisease among adults and children: an analysis of theCURE-CKD registry. JAMA Netw Open 2, 2019.

  25. W.W. Ismail, M.J. Witry, J.M. Urmie, The associationbetween cost sharing, prior authorization, and specialtydrug utilization: a systematic review. J Manag CareSpec Pharm 29 (2023) 449–463.

  26. H.J.L. Heerspink, P. Vart, N. Jongs et al. Estimatedlifetime benefit of novel pharmacological therapiesin patients with type 2 diabetes and chronic kidneydisease: a joint analysis of randomized controlledclinical trials. Diabetes Obes Metab 25 (2023) 3327–3336.

  27. Nuffield Department of Population Health RenalStudies Group. SGLT2 Inhibitor Meta-AnalysisCardio-Renal Trialists’ Consortium. Impact of diabeteson the effects of sodium glucose co-transporter-2inhibitors on kidney outcomes: collaborative metaanalysisof large placebo-controlled trials. Lancet 400(2022) 1788–1801.

  28. B. Fernández-Fernandez, P. Sarafidis, M.J. Soler etal. EMPA-KIDNEY: expanding the range of kidneyprotection by SGLT2 inhibitors. Clin Kidney J 16(2023) 1187–1198.

  29. P. McEwan, R. Boyce, J.J.G. Sanchez et al.Extrapolated longer-term effects of the DAPA-CKDtrial: a modelling analysis. Nephrol Dial Transplant38 (2023) 1260–1270.

  30. R. Vanholder, L. Annemans, M. Braks et al. Inequitiesin kidney health and kidney care. Nat Rev Nephrol 19(2023) 694–708.

  31. R. Agarwal, G. Filippatos, B. Pitt et al. Cardiovascularand kidney outcomes with finerenone in patientswith type 2 diabetes and chronic kidney disease: theFIDELITY pooled analysis. Eur Heart J 43 (2022)474–484.

  32. K.R. Tuttle, H. Bosch-Traberg, D.Z.I. Cherney etal. Post hoc analysis of SUSTAIN 6 and PIONEER 6trials suggests that people with type 2 diabetes at highcardiovascular risk treated with semaglutide experiencemore stable kidney function compared with placebo.Kidney Int 103 (2023) 772–781.

  33. R. Rubin, It takes an average of 17 years forevidence to change practice-the burgeoning field ofimplementation science seeks to speed things up.JAMA 329 (2023) 1333–1336.

  34. World Health Organization. Mid-point evaluation ofthe implementation of the WHO global action planfor the prevention and control of noncommunicablediseases 2013–2020 (NCD-GAP). Accessed November18, 2023. https://cdn.who.int/media/docs/defaultsource/documents/about-us/evaluation/ncd-gap-finalreport.pdf?sfvrsn=55b22b89_5&download=true

  35. M.E. Kruk, A.D. Gage, N.T. Joseph et al. Mortalitydue to low-quality health systems in the universalhealth coverage era: a systematic analysis of amenabledeaths in 137 countries. Lancet 392 (2018) 2203–2212.

  36. P. Kingori, K. Peeters Grietens, S. Abimbola et al.Uncertainties about the quality of medical productsglobally: lessons from multidisciplinary research. BMJGlob Health 6, 2023.

  37. Pan American Health Organization Quality controlof medicines. Accessed November 18, 2023. https://www.paho.org/en/topics/quality-control-medicines.

  38. K.R. Tuttle, L. Wong, W. St Peter et al. Moving fromevidence to implementation of breakthrough therapiesfor diabetic kidney disease. Clin J Am Soc Nephrol 17(2022) 1092–1103.

  39. R. Kalyesubula, A.L. Conroy, V. Calice-Silva et al.Screening for kidney disease in low- and middleincomecountries. Semin Nephrol 42, 2022.

  40. A. Francis, M.I. Abdul Hafidz, U.E. Ekrikpo et al.Barriers to accessing essential medicines for kidneydisease in low- and lower middle-income countries.Kidney Int 102 (2022) 969–973.

  41. J. Rangaswami, K. Tuttle, M. Vaduganathan,Cardio-renal-metabolic care models: toward achievingeffective interdisciplinary care. Circ Cardiovasc QualOutcomes 13, 2020.

  42. J.J. Neumiller, R.Z. Alicic, K.R. Tuttle, Overcomingbarriers to implementing new therapies for diabetickidney disease: lessons learned. Adv Chronic KidneyDis 28 (2021) 318–327.

  43. S.R. Mishra, D. Neupane, D. Preen et al. Mitigationof non-communicable diseases in developing countrieswith community health workers. Global Health 11(2015) 43.

  44. R. Joshi, O. John, V. Jha, The potential impact ofpublic health interventions in preventing kidneydisease. Semin Nephrol 37 (2017) 234–244.

  45. A. Patel, D. Praveen, A. Maharani et al. Associationof multifaceted mobile technology-enabled primarycare intervention with cardiovascular disease riskmanagement in rural Indonesia. JAMA Cardiol 4(2019) 978–986.

  46. A. Ardavani, F. Curtis, K. Khunti et al. The effectof pharmacist-led interventions on the managementand outcomes in chronic kidney disease (CKD): asystematic review and meta-analysis protocol. HealthSci Rep 6, 2023.

  47. C.F. Sherrod, S.L. Farr, A.J. Sauer, Overcomingtreatment inertia for patients with heart failure: howdo we build systems that move us from rest to motion?Eur Heart J 44 (2023) 1970–1972.

  48. C. Ramakrishnan, N.C. Tan, S. Yoon et al.Healthcare professionals’ perspectives on facilitatorsof and barriers to CKD management in primary care:a qualitative study in Singapore clinics. BMC HealthServices Res 22 (2022) 560.

  49. J. Porter, C. Boyd, M.R. Skandari et al. Revisitingthe time needed to provide adult primary care. J GenIntern Med 38 (2023) 147–155.

  50. C.A. Peralta, J. Livaudais-Toman, M. Stebbins et al.Electronic decision support for management of CKDin primary care: a pragmatic randomized trial. Am JKidney Dis 76 (2020) 636–644.

  51. P. Rios, L. Sola, A. Ferreiro et al. Adherence tomultidisciplinary care in a prospective chronic kidneydisease cohort is associated with better outcomes.PLoS One 17, 2022.

  52. J.K. Stevenson, Z.C. Campbell, A.C. Webster etal. eHealth interventions for people with chronickidney disease. Cochrane Database Syst Rev 8 (2019)Cd012379.

  53. D.S. Tuot, S.T. Crowley, L.A. Katz et al. Usabilitytesting of the kidney score platform to enhancecommunication about kidney disease in primary caresettings: qualitative think-aloud study. JMIR FormRes 6, 2022.

  54. W.R. Verberne, A.M. Stiggelbout, W.J.W. Bos et al.Asking the right questions: towards a person-centeredconception of shared decision-making regardingtreatment of advanced chronic kidney disease in olderpatients. BMC Med Ethics 23 (2022) 47.

  55. A. Taha, Y. Iman, J. Hingwala et al. Patient navigatorsfor CKD and kidney failure: a systematic review.Kidney Med 4, 2022.

  56. B.M. Essue, M. Laba, F. Knaul et al. Economicburden of chronic ill health and injuries for householdsin low- and middle-income countries. in: D.T. Jamison,H. Gelband, S. Hortonet al. (Eds.), Disease ControlPriorities: Improving Health and Reducing Poverty.3rd ed. The International Bank for Reconstructionand Development/The World Bank; 2017. https://doi.org/10.1596/978-1-4648-0527-1_ch6

  57. R. Khatib, M. McKee, H. Shannon et al. Availabilityand affordability of cardiovascular disease medicinesand their effect on use in high-income, middle-income,and low-income countries: an analysis of the PUREstudy data. Lancet 387 (2016) 61–69.

  58. N. Kamath, A.A. Iyengar, Chronic kidney disease(CKD): an observational study of etiology, severity andburden of comorbidities. Indian J Pediatr 84 (2017)822–825.

  59. L. Cirillo, F. Ravaglia, C. Errichiello et al. Expectationsin children with glomerular diseases from SGLT2inhibitors. Pediatr Nephrol 37 (2022) 2997–3008.

  60. J.F. Donohue, J.S. Elborn, P. Lansberg et al. Bridgingthe “know-do” gaps in five non-communicable diseasesusing a common framework driven by implementationscience. J Healthc Leadersh 15 (2023) 103–119.70 ISSN 0326-3428www.renal.org.ar Rev Nefrol Diál Traspl. 2024;44(2):53-70 /

  61. Population Health Research Institute. Polypills addedto WHO essential medicines list. Accessed November18, 2023. https://www.phri.ca/eml/.

  62. S.G. Sepanlou, J.F.E. Mann, P. Joseph et al. Fixed-dosecombination therapy for prevention of cardiovasculardiseases in CKD: an individual participant data metaanalysis.Clin J Am Soc Nephrol 18 (2023) 1408–1415.

  63. V. Dev, A. Mittal, V. Joshi et al. Cost analysis oftelemedicine use in paediatric nephrology-the LMICperspective. Pediatr Nephrol 39 (2024) 193–201.

  64. N. Musacchio, R. Zilich, P. Ponzani et al. Transparentmachine learning suggests a key driver in the decisionto start insulin therapy in individuals with type 2diabetes. J Diabetes 15 (2023) 224–236.

  65. C. Zuniga, C. Riquelme, H. Muller et al. Usingtelenephrology to improve access to nephrologist andglobal kidney management of CKD primary carepatients. Kidney Int Rep 5 (2020) 920–923.

  66. D.E.M. van der Horst, N. Hofstra, C.F. van Uden-Kraan et al. Shared decision making in health carevisits for CKD: patients’ decisional role preferencesand experiences. Am J Kidney Dis 82 (2023) 677–686.

  67. B. Hole, M. Scanlon, C. Tomson, Shared decisionmaking: a personal view from two kidney doctors anda patient. Clin Kidney J 16 (2023) i12–i19.




2020     |     www.medigraphic.com